BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MODAG GmbH readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies MODAG GmbH's drugs run\, from Cli
 nicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06568237-1679@assetmemo.bio
DTSTAMP:20261121T005448Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:Emrusolmin: Phase 2 readout est. (NCT06568237)
DESCRIPTION:Emrusolmin\, phase 2.\nStudy: A Trial to Test if TEV-56286 is E
 ffective for Treatment of Participants With Multiple System Atrophy\nEstim
 ated primary completion: 15 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/emrusolmin#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06568237
URL:https://assetmemo.bio/drug/emrusolmin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07197866-1679@assetmemo.bio
DTSTAMP:20261121T005448Z
DTSTART;VALUE=DATE:20290503
DTEND;VALUE=DATE:20290504
SUMMARY:Emrusolmin: Phase 2 readout est. (NCT07197866)
DESCRIPTION:Emrusolmin\, phase 2.\nStudy: An Extension Trial to Test if TEV
 -56286 is Effective in Relieving Multiple System Atrophy\nEstimated primar
 y completion: 3 May 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/emrusolmin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07197866
URL:https://assetmemo.bio/drug/emrusolmin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
